Effect of MCP-1 and CCR2 Serum Levels on COVID-19 Severity

Abstract

Objective: Approximately 80% of people with coronavirus disease 2019 (COVID-19) are asymptomatic, and only a small proportion of cases show serious consequences leading to hospitalization. The interplay between chemokines and their receptors can affect the severity of several infectious diseases, such as severe acute respiratory syndrome and Middle East Respiratory Syndrome. The interplay of monocyte chemoattractant protein-1 (MCP-1) with its receptor C-C motif chemokine receptor 2 (CCR2) may affect the pathogenesis of COVID-19 by functioning in the dispatch of lymphocytes and monocytes/macrophages to the infection site. Materials and Methods: The serum MCP-1 and CCR2 concentrations were measured using the enzyme-linked immunosorbent assay (ELISA) in 49 asymptomatic, 50 severe, and 57 critical COVID-19 cases. Results: Serum MCP-1 levels were considerably higher in critical cases than in cases in the other two groups, suggesting an increased risk for disease severity (p = 0.008; p = 0.01, respectively). Serum CCR2 levels were significantly higher in asymptomatic cases than in critical cases suggesting a protective role against disease severity (p = 0.001). Conclusion: MCP-1 and CCR2 may be candidate biomarkers for the prediction of disease severity. Therefore, by measuring serum levels of MCP-1 and CCR2 early, the disease course can be predicted , and necessary precautions can be taken before the disease becomes severe.

Keywords

• MCP-1
• CCR2
• COVID-19 severity
• risk factors
• candidate biomarkers

References

1. 1. Wang EY, Mao T, Klein J, Dai Y, Huck JD, Jaycox JR, et al. Diverse functional autoantibodies in patients with COVID-19. Nature 2021; 595(7866): 283-8. google scholar
2. 2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497-506. google scholar
3. 3. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; 323(11): 1061-69. google scholar
4. 4. Frater JL, Zini G, d’Onofrio G, Rogers HJ. COVID-19 and the clinical hematology laboratory. Int J Lab Hematol 2020; 42(Suppl 1): 11-8. google scholar
5. 5. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk 18. factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395(10229): 1054-62. google scholar
6. 6. Nakeshbandi M, Maini R, Daniel P, Rosengarten S, Parmar P, Wilson C, et al. The impact of obesity on COVID-19 complications: a retrospective cohort study. Int J Obes (Lond) 2020; 44(9): 1832-7. google scholar
7. 7. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. 20. Pathophysiology, transmission, diagnosis, and treatment of Coronavirus Disease 2019 (COVID-19): a review. JAMA 2020; 324(8): 782-93. google scholar
8. 8. Teijaro JR, Walsh KB, Rice S, Rosen H, Oldstone MB. Mapping the 22. innate signaling cascade essential for cytokine storm during influenza virus infection. Proc Natl Acad Sci U S A 2014; 111(10): 3799-804. google scholar

9. 9. Maccio A, Oppi S, Madeddu C. COVID-19 and cytokine storm syndrome: can what we know about interleukin-6 in ovarian cancer be applied? J Ovarian Res 2021; 14(1): 28. google scholar
10. 10. Zhao Y, Qin L, Zhang P, Li K, Liang L, Sun J, et al. Longitudinal 24. COVID-19 profiling associates IL-1RA and IL-10 with disease severity and RANTES with mild disease. JCI Insight 2020; 5(13): e139834. 25. google scholar
11. 11. Chen Y, Wang J, Liu C, Su L, Zhang D, Fan J, et al. IP-10 and MCP-1 as biomarkers associated with disease severity of COVID-19. Mol Med 2020; 26(1): 97. google scholar
12. 12. Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, 26. M0ller R, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell 2020; 181(5): 1036-45.e9. google scholar
13. 13. Rotondi M, Chiovato L, Romagnani S, Serio M, Romagnani P. Role 27. of chemokines in endocrine autoimmune diseases. Endocr Rev 2007; 28(5): 492-520. google scholar
14. 14. Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon 28. Cytokine Res 2009; 29(6): 313-26. google scholar
15. 15. Fantuzzi L, Tagliamonte M, Gauzzi MC, Lopalco L. Dual CCR5/CCR2 targeting: opportunities for the cure of complex disorders. Cell Mol Life Sci 2019; 76(24): 4869-86. google scholar
16. 16. Cabaro S, D’Esposito V, Di Matola T, Sale S, Cennamo M, Terracciano 29. D, et al. Cytokine signature and COVID-19 prediction models in the two waves of pandemics. Sci Rep 2021; 11(1): 20793. google scholar
17. 17. Ogawa H, Iimura M, Eckmann L, Kagnoff MF. Regulated production of the chemokine CCL28 in human colon epithelium. Am J Physiol 30. Gastrointest Liver Physiol 2004; 287(5): G1062-9. google scholar
18. 18. S0rensen TL, Tani M, Jensen J, Pierce V, Lucchinetti C, Folcik VA, et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 1999; 103(6): 807-15. google scholar
19. 19. Nelken NA, Coughlin SR, Gordon D, Wilcox JN. Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest 1991; 88(4): 1121-7. google scholar
20. 20. Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, et al. Coronavirus infections and immune responses. J Med Virol 2020; 92(4): 424-32. google scholar
21. 21. Kawabata K, Hagio T, Matsuoka S. The role of neutrophil elastase in acute lung injury. Eur J Pharmacol 2002; 451(1): 1-10. google scholar
22. 22. Peiris JS, Guan Y, Yuen KY. Severe acute respiratory syndrome. Nat Med 2004; 10(12 Suppl): 88-97. google scholar
23. 23. Zhou J, Chu H, Li C, Wong BH, Cheng ZS, Poon VK, et al. Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: implications for pathogenesis. J Infect Dis 2014; 209(9): 1331-42. google scholar
24. 24. Lin L, Lu L, Cao W, Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect 2020; 9(1): 727-32. google scholar
25. 25. Bülow Anderberg S, Luther T, Berglund M, Larsson R, Rubertsson S, Lipcsey M, et al. Increased levels of plasma cytokines and correlations to organ failure and 30-day mortality in critically ill Covid-19 patients. Cytokine 2021; 138: 155389. google scholar
26. 26. Dogan S, Mart Komurcu SZ, Korkmaz MD, Kaya E, Yavas S, Dogan S, et al. Effect of chemokine gene variants on Covid-19 disease severity. Immunol Invest 2022; 51(7): 1965-74. google scholar
27. 27. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020; 180(7): 934-43. google scholar
28. 28. Jafarzadeh A, Chauhan P, Saha B, Jafarzadeh S, Nemati M. Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: lessons from SARS and MERS, and potential therapeutic interventions. Life Sci 2020; 257: 118102. google scholar
29. 29. Sheahan T, Morrison TE, Funkhouser W, Uematsu S, Akira S, Baric RS, et al. MyD88 is required for protection from lethal infection with a mouse-adapted SARS-CoV. PLoS Pathog 2008; 4(12): e1000240. google scholar
30. 30. Pairo-Castineira E, Clohisey S, Klaric L, Bretherick AD, Rawlik K, Pasko D, et al. Genetic mechanisms of critical illness in COVID-19. Nature 2021; 591(7848): 92-8. google scholar